Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore.

IF 5.5 3区 医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2023-12-12 DOI:10.1080/14760584.2023.2290931
Karan Thakkar, Julia Spinardi, Moe H Kyaw, Jingyan Yang, Carlos Fernando Mendoza, Egemen Ozbilgili, Bulent Taysi, Josie Dodd, Ben Yarnoff, Helen M Oh
{"title":"Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore.","authors":"Karan Thakkar, Julia Spinardi, Moe H Kyaw, Jingyan Yang, Carlos Fernando Mendoza, Egemen Ozbilgili, Bulent Taysi, Josie Dodd, Ben Yarnoff, Helen M Oh","doi":"10.1080/14760584.2023.2290931","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 has been a dynamically changing virus, requiring the development of adapted vaccines. This study estimated the potential public health impact alternative vaccination strategies for COVID-19 in Singapore.</p><p><strong>Research design and methods: </strong>The outcomes of alternative vaccination strategies with a future adapted vaccine were estimated using a combined Markov decision tree model. The population was stratified by high- and standard-risk. Using age-specific inputs informed by local surveillance data and published sources, the model estimated health (case numbers, hospitalizations, and deaths) and economic (medical costs and productivity losses) outcomes in different age and risk subpopulations.</p><p><strong>Results: </strong>Booster vaccination in only the elderly and high-risk subpopulation was estimated to avert 278,614 cases 21,558 hospitalizations, 239 deaths, Singapore dollars (SGD) 277 million in direct medical costs, and SGD 684 million in indirect medical costs. These benefits increased as vaccination was expanded to other subpopulations. Increasing the booster vaccination coverage to 75% of the standard-risk population averted more deaths (3%), hospitalizations (29%), infections (145%), direct costs (90%), and indirect costs (192%) compared to the base case.</p><p><strong>Conclusions: </strong>Broader vaccination strategies using an adapted booster vaccine could have substantial public health and economic impact in Singapore.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"16-26"},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2023.2290931","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 has been a dynamically changing virus, requiring the development of adapted vaccines. This study estimated the potential public health impact alternative vaccination strategies for COVID-19 in Singapore.

Research design and methods: The outcomes of alternative vaccination strategies with a future adapted vaccine were estimated using a combined Markov decision tree model. The population was stratified by high- and standard-risk. Using age-specific inputs informed by local surveillance data and published sources, the model estimated health (case numbers, hospitalizations, and deaths) and economic (medical costs and productivity losses) outcomes in different age and risk subpopulations.

Results: Booster vaccination in only the elderly and high-risk subpopulation was estimated to avert 278,614 cases 21,558 hospitalizations, 239 deaths, Singapore dollars (SGD) 277 million in direct medical costs, and SGD 684 million in indirect medical costs. These benefits increased as vaccination was expanded to other subpopulations. Increasing the booster vaccination coverage to 75% of the standard-risk population averted more deaths (3%), hospitalizations (29%), infections (145%), direct costs (90%), and indirect costs (192%) compared to the base case.

Conclusions: Broader vaccination strategies using an adapted booster vaccine could have substantial public health and economic impact in Singapore.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在新加坡使用适应疫苗对不同COVID-19疫苗接种策略的潜在公共卫生影响进行建模
背景:引起COVID-19的严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是一种动态变化的病毒,需要开发适应疫苗。本研究估计了新加坡COVID-19替代疫苗接种策略的潜在公共卫生影响。研究设计和方法:使用联合马尔可夫决策树模型估计未来适应疫苗的替代疫苗接种策略的结果。人群按高风险和标准风险分层。该模型利用当地监测数据和公开来源提供的特定年龄输入,估计了不同年龄和风险亚人群的健康(病例数、住院和死亡)和经济(医疗费用和生产力损失)结果。结果:仅在老年人和高危亚人群中加强疫苗接种估计可避免278,614例病例,21,558例住院,239例死亡,直接医疗费用为2.77亿新元,间接医疗费用为6.84亿新元。随着疫苗接种扩展到其他亚群,这些益处也会增加。与基本情况相比,将加强疫苗接种覆盖率提高到标准风险人群的75%可避免更多的死亡(3%)、住院(29%)、感染(145%)、直接费用(90%)和间接费用(192%)。结论:在新加坡,使用适应性加强疫苗的更广泛的疫苗接种策略可能对公共卫生和经济产生重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Vaccines
Expert Review of Vaccines 医学-免疫学
CiteScore
9.10
自引率
3.20%
发文量
136
审稿时长
4-8 weeks
期刊介绍: Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
期刊最新文献
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the omicron BA.2.86/JN.1 period among older adults in seven European countries: a VEBIS-EHR network study. Adult vaccination in three Eastern Mediterranean countries: current status, challenges and the way forward. Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomized clinical trial. A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. Estimating the time required to reach HPV vaccination targets across Europe.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1